Skip to content
Peptigraph home

GHK-Cu and Melanotan II Together: What Is Known

GHK-Cu and Melanotan II taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Copper tripeptideInjectable off Category 2 (Apr 2026)GHK-CuCopper tripeptide with mostly topical or cosmetic human data; a small randomized laser-resurfacing study found no statistically significant differences between groups for earlier resolution of erythema.[3]Skin & hairMelanocortin agonistOff FDA Category 2 (Apr 2026)Melanotan IIUnlicensed melanocortin agonist with no FDA-approved product; controlled data are small, such as penile erection in 17 of 20 men without sexual stimulation.[13]Sexual & hormonal health
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 7 of 11 fields where the two differ. PCAC vote, Jul 2026, WADA, Half-life, Evidence strength are the same or both unknown.

FieldGHK-CuMelanotan II
ClassCopper tripeptideMelanocortin agonist
Also calledcopper peptide, copper tripeptide-1, GHKMT2, MT-II
CategorySkin & hairSexual & hormonal health
FDA statusInjectable off Category 2 (Apr 2026)Off FDA Category 2 (Apr 2026)
Human studies we summarised5 human (2 randomized or controlled) of 15 summarised12 human (2 randomized or controlled) of 14 summarised
Typical study doses
Vial sizes sold50 mg, 100 mg, 200 mg10 mg

Melanotan II: pigmentation, erections and case reports

In a double-blind crossover study, Melanotan II led to penile erection in 17 of 20 men, with 12.9% of subjects reporting severe nausea at the dose studied.[13]

A case report describes a patient who self-injected MT-II for 3 to 4 weeks, intending to augment sunbed tanning, before a melanoma was excised.[22]

GHK-Cu skin trial data

For GHK-Cu, the laser-resurfacing trial found no statistically significant difference between groups on erythema resolution.[3]

The GHK-Cu review says most randomized trials are small and conducted on facial cosmetic creams.[23]

Earlier Melanotan II work

An early pilot reported increased pigmentation in two subjects after Melanotan II dosing.[14]

Together

The GHK-Cu with Melanotan II search returned 0 PubMed records.

Calculated from pubmed query ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("melanotan II"[tiab] OR "melanotan 2"[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key ghk-cu__melanotan-2); no arithmetic applied.

FDA removed Melanotan II from category 2 after nominators withdrew, and set a committee consultation before the end of February 2027.[24]

Common questions

Can you take GHK-Cu with melanotan 2?

No study of the pair was found. The melanoma case report concerns MT-II used with sunbeds, not GHK-Cu.[22]

GHK-Cu and MT2: is there evidence on the two?

No. The Melanotan II nausea figure comes from a study of Melanotan II alone.[13]

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Archives of facial plastic surgery · 2006PMID 16847171Accessed 2 Oct 2026
  4. 4Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
  5. 5PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.International journal of impotence research · 2000PMID 11035391Accessed 2 Oct 2026
  14. 14Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.Life sciences · 1996PMID 8637402Accessed 2 Oct 2026
  15. 15Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.Clinical toxicology (Philadelphia, Pa.) · 2012PMID 23121206Accessed 2 Oct 2026
  16. 16PubMed search: "melanotan II"[tiab] OR "melanotan 2"[tiab] (198 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: ("melanotan II"[tiab] OR melanotan[tiab]) AND humans[mh] (82 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: ("melanotan II"[tiab] OR "melanotan 2"[tiab] OR melanotan[ti]) AND (case[tiab] OR naevi[tiab] OR nevi[tiab] OR melanoma[tiab] OR adverse[tiab] OR priapism[tiab] OR tanning[tiab] OR sunless[tiab]) AND humans[mh] (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: ("melanotan II"[tiab] OR "melanotan 2"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("melanotan II"[tiab] OR "melanotan 2"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  22. 22Melanoma associated with the use of melanotan-II.Dermatology (Basel, Switzerland) · 2014PMID 24355990Accessed 2 Oct 2026
  23. 23A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.Archives of internal medicine research · 2026PMID 42787770Accessed 2 Oct 2026
  24. 24Official web pageOfficial web page · web page

Found an error? Report a correction.